FibroGen Inc. (NASDAQ:FGEN) shares were up 3% on Monday . The stock traded as high as $19.15 and last traded at $18.96, with a volume of 202,756 shares traded. The stock had previously closed at $18.41.

Several research analysts have recently weighed in on FGEN shares. Credit Suisse Group AG reaffirmed a “buy” rating on shares of FibroGen in a research report on Tuesday, July 12th. Zacks Investment Research raised FibroGen from a “sell” rating to a “hold” rating in a research report on Tuesday, May 10th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. FibroGen currently has an average rating of “Buy” and a consensus price target of $33.25.

The company’s market capitalization is $1.20 billion. The company’s 50-day moving average is $18.21 and its 200 day moving average is $18.29.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported $0.35 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.36 by $0.01. Equities analysts predict that FibroGen Inc. will post ($1.26) EPS for the current fiscal year.

In related news, CFO Pat Cotroneo sold 1,796 shares of the business’s stock in a transaction dated Wednesday, June 15th. The stock was sold at an average price of $16.49, for a total value of $29,616.04. Following the completion of the sale, the chief financial officer now directly owns 138,114 shares of the company’s stock, valued at approximately $2,277,499.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider K Peony Yu sold 2,344 shares of the business’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $17.96, for a total value of $42,098.24. Following the completion of the sale, the insider now directly owns 210,257 shares of the company’s stock, valued at $3,776,215.72. The disclosure for this sale can be found here.

An institutional investor recently raised its position in FibroGen stock. Rhumbline Advisers boosted its position in shares of FibroGen Inc. (NASDAQ:FGEN) by 8.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,940 shares of the biopharmaceutical company’s stock after buying an additional 3,675 shares during the period. Rhumbline Advisers owned about 0.07% of FibroGen worth $1,400,000 at the end of the most recent quarter.

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.